Fit-for-purpose biomarker immunoassay qualification and validation: three case studies

Area of Science:

• Biomarker Discovery and Development
• Assay Qualification and Validation
• Pharmacology and Toxicology

Background:

• Efficient biomarker assay readiness is crucial for supporting drug development programs.
• Reliable biomarker data is essential for decision-making throughout the drug development lifecycle.
• Existing methods may not always align with the specific needs of diverse drug programs.

Purpose of the Study:

• To enhance the efficiency of biomarker assay readiness.
• To generate reliable biomarker data for three distinct drug programs.
• To implement and evaluate a fit-for-purpose approach for assay development.

Main Methods:

• Implemented a fit-for-purpose strategy for biomarker assay development.
• Qualified two exploratory biomarker assays (CXCL1, CCL19) based on intended data use.
• Validated a third biomarker assay (IL-6) for patient safety monitoring in early-phase clinical trials.

Main Results:

• All three biomarker assays (CXCL1, CCL19, IL-6) successfully passed pre-defined acceptance criteria.
• The qualification and validation strategies were tailored to the specific requirements of each biomarker and its intended application.
• The fit-for-purpose approach demonstrated effectiveness in supporting programs at various stages of drug development.

Conclusions:

• The fit-for-purpose approach provides a flexible and efficient strategy for biomarker assay development.
• Tailored qualification (minimum, full) and validation methods ensure assay suitability for specific drug development needs.
• This methodology enhances the reliability of biomarker data, supporting critical decisions in drug discovery and clinical trials.